Predicting Expected Absolute Chemotherapy Treatment Benefit in Women With Early-Stage Breast Cancer Using EndoPredict, an Integrated 12-Gene Clinicomolecular Assay. by Soliman, H et al.
original
report
Predicting Expected Absolute Chemotherapy
Treatment Beneﬁt in Women With Early-Stage
Breast Cancer Using EndoPredict, an Integrated
12-Gene Clinicomolecular Assay
Hatem Soliman, MD1; Darl D. Flake II, PhD2; Anthony Magliocco, MD1; Mark Robson, MD3; Lee Schwartzberg, MD4;
Priyanka Sharma, MD5; Krystal Brown, PhD2; Saskia Wehnelt2; Ralf Kronenwett, MD, PhD6; Alexander Gutin, PhD2;
Johnathan Lancaster, MD, PhD2; Jack Cuzick, PhD7; and William Gradishar, MD8
abstract
PURPOSE Previous studies have shown EndoPredict (EPclin), a test that integrates 12-gene expression data with
nodal status and tumor size, to be predictive for risk of distant recurrence in women with estrogen
receptor–positive, human epidermal growth factor receptor 2–negative early-stage breast cancer. Here, we
modeled expected absolute chemotherapy beneﬁt on the basis of EPclin test results.
METHODS The effect of chemotherapy was modeled using previously validated 10-year risk of distant recurrence
as a function of EPclin score for patients treated without chemotherapy. Average relative chemotherapy beneﬁt
to reduce breast cancer distant recurrence was evaluated using a published meta-analysis from the Early Breast
Cancer Trialists’ Collaborative Group. Absolute chemotherapy beneﬁt differences were estimated across a range
of interaction strengths between relative chemotherapy beneﬁt and EPclin score. The average absolute beneﬁt
was calculated for patients with high and low EPclin scores using the distribution of scores in 2,185 samples
tested by Myriad Genetics.
RESULTS The average expected absolute beneﬁt of chemotherapy treatment for patients with a low EPclin score
was 1.8% in the absence of interaction and 1.5% for maximal interaction. Conversely, the expected average
absolute chemotherapy beneﬁt for patients with a high EPclin score was 5.3% and 7.3% for no interaction and
maximal interaction, respectively.
CONCLUSION For women with estrogen receptor–positive, human epidermal growth factor receptor 2–negative
early-stage breast cancer, a high EPclin score identiﬁed which patients would beneﬁt most from adjuvant
chemotherapy in terms of absolute reduction of distant recurrence, regardless of the amount of interaction
between EPclin and relative chemotherapy beneﬁt. A high degree of prognostic discrimination for distant
recurrence is more important for identifying patients likely to beneﬁt most from chemotherapy than an in-
teraction between EPclin and treatment-relative beneﬁt.
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INTRODUCTION
One in eight women in the United States will develop
invasive breast cancer during her lifetime, and more
than 40,000 women were expected to die as a result of
the disease in 2018.1 Approximately 80% of primary
breast cancers are estrogen receptor (ER) positive,2
such that adjuvant endocrine therapy (ET) after sur-
gery is associated with improved outcomes and is now
standard practice.3-5 In addition to ET, a subset of
patients beneﬁt from the addition of chemotherapy
(ET + C). The Early Breast Cancer Trialists’ Collaborative
Group performed a meta-analysis of more than 100
clinical trials in more than 100,000 women to evaluate
the beneﬁt of adjuvant chemotherapy.6 Although the
beneﬁt in individual trials varied considerably,3 this
meta-analysis demonstrated an average 30% relative
reduction in distant recurrence among women who
received chemotherapy compared with those who
did not.6
For many patients with ER-positive disease, the risk of
distant recurrence is sufﬁciently low that ET alone is
adequate. In these patients, the adverse effects as-
sociated with chemotherapy may outweigh any beneﬁt
provided by a reduced risk of disease recurrence.
Historically, identiﬁcation of these low-risk patients has
relied on clinicopathologic parameters, such as nodal
status, tumor size, and tumor grade. However, studies
have shown that clinicopathologic features alone
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are inadequate to guide adjuvant chemotherapy decisions
reliably.7 Thus, when risk is deﬁned using clinicopathologic
features alone, a subset of truly low-risk patients receives
unnecessary chemotherapy, whereas others at high risk
forgo chemotherapy and experience avoidable disease
recurrence.
To address this clinical dilemma, multigene expression
prognostic assays have been developed for patients with
ER-positive, human epidermal growth factor receptor 2
(HER2)–negative early-stage breast cancer. Several such
assays are clinically available, with variable performance
according to nodal status, and early (0 to 5 years) versus
late (5 or more years) recurrence.8-11 These assays better
quantify residual risk of recurrence after surgery and ET
than clinicopathologic features alone, which enables
physicians to tailor the use of adjuvant therapies (ET alone v
ET + C) more accurately. To this end, evidence-based
practice guidelines now indicate that prognostic assays
are appropriate tools to help guide decision making.12-14
One such test is EndoPredict (Myriad Genetics, Salt Lake
City, UT), which integrates a 12-gene molecular score with
nodal status and tumor size into a combined clin-
icomolecular score (EPclin). Previous studies have vali-
dated that EPclin accurately predicts the risk of distant
metastases in patients with ER-positive, HER2-negative
breast cancers.11,15-18 Although this information can re-
liably identify patients at sufﬁciently low risk so that che-
motherapy may be avoided safely, the ability of EPclin to
predict beneﬁt from the addition of chemotherapy has yet to
be fully deﬁned. Ideal approaches to evaluate this are
limited because archival samples from previous random-
ized trials of ET 6 C in appropriate patients largely have
been exhausted.3,5 A prospective trial of EPclin that in-
cludes an arm randomized to receive no chemotherapy
would now be unethical, given the established beneﬁt of
chemotherapy for patients with high-risk disease. Alter-
native study designs, therefore, are required to explore the
scope of EPclin’s ability to predict adjuvant chemotherapy
beneﬁt for patients with ER-positive, HER2-negative early-
stage breast cancer.
So far, classic factors that inﬂuence breast cancer prog-
nosis have not shown an interaction between the relative
effect of adjuvant chemotherapy on absolute risk of
recurrence.19 Furthermore, the absolute beneﬁt of che-
motherapy depends on the patient’s baseline risk of de-
veloping recurrent disease.19 As such, as we evaluate
a biomarker, it is helpful to understand the principal drivers
of its chemopredictive ability. One possibility is that che-
mopredictive ability is driven by high prognostic accuracy,
that is, the ability of the biomarker to differentiate those
patients at highest versus lowest absolute risk of recurrence
and, thus, those latter patients for whom chemotherapy
cannot yield any clinically meaningful beneﬁt. Alternatively,
it is possible that a biomarker’s chemopredictive ability is
driven by differences in relative chemotherapy beneﬁt
between higher versus lower biomarker-deﬁned patient
groups (ie, interaction between the biomarker score and
relative chemotherapy beneﬁt).
In the current study, we describe a modeling study that
uses EPclin score, absolute risk of recurrence, and re-
duction of this risk associated with the addition of che-
motherapy to estimate the differences in absolute risk for
distant recurrence across EPclin scores. We demonstrate
that for a molecular marker such as EPclin, patients with
the highest baseline absolute risk for recurrence experi-
ence the greatest absolute beneﬁt from chemotherapy.
Furthermore, we establish that the key factor in any bio-
marker’s chemopredictive capacity is the ability to predict
accurately the baseline absolute risk of recurrence. Any
interaction of the biomarker with relative chemotherapy
CONTEXT
Key Objective
Can an integrated, 12-gene, clinicomolecular assay predict absolute beneﬁt from chemotherapy for women with estrogen
receptor (ER)–positive, human epidermal growth factor receptor 2 (HER2)–negative breast cancer?
Knowledge Generated
In this model, patients with low 12-gene scores showed no difference in recurrence-free survival with or without chemo-
therapy, whereas those with high 12-gene scores showed amarked increase in recurrence-free survival with the addition of
chemotherapy. Overall, this study suggests that the 12-gene clinicomolecular score is able to predict absolute beneﬁt of
chemotherapy for women with ER-positive, HER2-negative breast cancer.
Relevance
Accurate risk assessment is critical for determining appropriate treatment of women with breast cancer. Breast cancer
prognostic assays like the 12-gene clinicomolecular score have been shown to provide more information about risk than
standard clinical information alone in predicting recurrence-free survival in the absence of treatment. These new data
support the ability of the 12-gene clinicomolecular score to also predict absolute beneﬁt from chemotherapy to help to guide
chemotherapy decisions for women with ER-positive, HER2-negative breast cancer.
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beneﬁt will play only a small role in the absolute risk of
recurrence. Through this modeling, we estimate the dif-
ferences in absolute risk of distant recurrence across EPclin
scores and examine the impact of different amounts of
statistical interaction between EPclin and chemotherapy on
these estimates.
METHODS
Gene Expression Assay
The 12-gene mRNA expression assay has been previously
described in detail.20-22 In brief, the expression of three
proliferation-related target genes (BIRC5, DHCR7, UBE2C),
ﬁve hormone receptor–related target genes (AZGP1, IL6ST,
MGP, RBBP8, STC2), and three normalization genes
(CALM2, OAZ1, RPL37A) were measured by reverse-
transcription quantitative polymerase chain reaction. A 12-
gene molecular score was calculated as the linear combi-
nation of the normalized target gene expression.11,22 The
clinicomolecular score EPclin was calculated by combining
the 12-gene molecular score with tumor size and the
number of positive lymph nodes and was reported as
a numerical score from 1 to 6.11,22 Tumors with an EPclin
score of less than 3.3 are considered low risk for distant
recurrence and tumors with scores of 3.3 or greater are
considered high risk for distant recurrence.11,17,18
Statistical Methods
The ability of EPclin to provide an estimate of expected
chemotherapy beneﬁt was modeled, as shown in Figure 1.
The primary component was the prognostic value of EPclin
to predict the rate of distant recurrence in the ﬁrst 10 years
of follow-up. First, risk of 10-year distant recurrence in
patients treated with ET only (untreated) as a function of
EPclin score, runtreated(EPclin), was obtained from a pre-
viously published study of two large randomized phase III
trials from the Austrian Breast and Colorectal Cancer Study
Group (ABCSG-6 and ABCSG-8).11 Second, the risk of
Risk of 10-year distant metastasis without chemotherapy
The 10-year risk of distant recurrence in patients treated with endocrine therapy only (untreated) was
obtained from published results of the 12-gene expression assay in the ABCSG-6 and ABCSG-8 trials.10
Model risk of 10-year distant recurrence with chemotherapy
The 10-year risk of distant recurrence in patients treated with endocrine therapy and adjuvant
chemotherapy (treated) was modeled using the overall chemotherapy treatment benefit to reduce
recurrence in ER-positive, HER2-negative breast cancer from a meta-analysis by the
EBCTCG (HRoverall = 0.7).
3,18
ln(HRtreatment) = ln(HRoverall) − (EPclin − EPclinavg)
Risk of 10-year distant metastasis in untreated patients from part A
Risk of 10-year distant metastasis in treated patient
HRtreatment Relative chemotherapy benefit for an EPclin score
 Strength of interaction between HRtreatment and EPclin
EPclin Patient EPclin score
Risk of distant recurrence modeled from no interaction (min  = 0) between EPclin score and HRtreatment up
to maxiumum interation between EPclin score and HRtreatment (  max = –ln(HRoverall) / (EPclinavg – EPclinmin)
Calculate absolute benefit from chemotherapy
AB = runtreated – rtreated
rtreated =1 − (1 − runtreated)
HRtreatment
rtreated
runtreated
B
C
A



FIG 1. Overview of statistical methods to model chemotherapy beneﬁt as a function of EPclin score. (A) Risk of
10-year distant metastasis without chemotherapy. (B)Model risk of 10-year distance recurrencewith chemotherapy.
(C) Calculate absolute beneﬁt from chemotherapy. ABCSG, Austrian Breast and Colorectal Cancer Study Group;
EBCTCG, Early Breast Cancer Trialists’ Collaborative Group; ER, estrogen receptor; HER2, human epidermal growth
factor receptor 2.
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10-year distant recurrence in patients treated with ET + C
(treated) was estimated by introducing a relative chemo-
therapy beneﬁt for a particular EPclin score, HRtreatment, to
the untreated risk according to a proportional hazards
model (Fig 1B), as in Equation 1:
rtreated  1 −

1 − runtreated
HRtreatment (1)
Mathematically, the dependence of the relative chemo-
therapy beneﬁt on the risk of distant recurrence was
modeled using a main effect for chemotherapy and an
interaction between treatment status and the prognostic
signature.23 Interactions were modeled as a linear de-
pendence of the logarithm of HR for treatment on EPclin
score according to Equation 2:
ln

HRtreatment

 ln

HRoverall

− β

EPclin − EPclinavg

(2)
In this equation, β represents the interaction strength and
deﬁnes how strongly the relative chemotherapy beneﬁt for
a patient depends on EPclin score, EPclinavg is the mean
EPclin score in the population, and HRoverall is the hazard
ratio for the chemotherapy beneﬁt in the population. The
term ln(HRoverall) ensures that the overall beneﬁt of
chemotherapy in the population does not depend on the
interaction strength and matches the results from meta-
analysis by the Early Breast Cancer Trialists’ Collaborative
Group overview of more than 100 clinical trials that
evaluated the beneﬁt of adjuvant chemotherapy in more
than 100,000 women with breast cancer.6 On the basis of
this meta-analysis, the overall reduction in distant re-
currence rates for treatment was set at 30%, but 40% and
20% also were explored, corresponding to anHRoverall rate
of 0.7, 0.6, and 0.8, respectively.
Maximal interaction was deﬁned such that a patient’s
relative chemotherapy beneﬁt would be 0 at the minimum
EPclin score (EPclinmin = 1; Fig 1B. In this scenario, β was
equal to βmax = −ln(HRoverall) / (EPclinavg − EPclinmin). With
the maximum value of β determined for an interaction
giving no chemotherapy beneﬁt at EPclinmin, weaker in-
teractions were modeled using a percentage of the maxi-
mum value of β (Fig 1B).
Finally, the absolute beneﬁt AB from chemotherapy for
treated patients was determined according to Equation 3
(Fig 1C):
AB  runtreated − rtreated (3)
Absolute chemotherapy beneﬁt for the low-risk category
was calculated as a mean absolute chemotherapy
beneﬁt for all low-risk patients, and the same went for the
high-risk category. For this calculation, EPclin scores
were obtained from all patients tested with the 12-gene
molecular assay at Myriad Genetics between March 31
and December 11, 2017, or at Myriad International
(Munich, Germany) between October 13, 2014, and
December 8, 2017, who received valid test results.
Formalin-ﬁxed parafﬁn-embedded breast resections of
treatment-naı¨ve ER-positive, HER2-negative breast tis-
sue were tested. Biopsy samples were excluded. All data
were collected in the course of normal health care op-
erations. All patients provided consent for clinical testing
at the time of testing, and all patient data were de-
identiﬁed for analysis. These scores also were used to
calculate EPclinavg.
RESULTS
We examined the impact of different magnitudes of
treatment effect and interaction strengths on the estimated
10-year risk of distant recurrence (Table 1). Maximal in-
teraction strength (βmax = 0.159) was ﬁrst determined by
assuming that a patient’s relative chemotherapy beneﬁt is
0 at the lowest possible EPclin score and maintaining the
HRoverall of treatment at 0.7. The corresponding HRtreatment
as a function of EPclin score is shown in Figure 2.
HRtreatment is 1 for a patient with an EPclin score of 1 and
0.45 for a patient with the maximum observed EPclin score
of 6. The risk of distant recurrence in the treated arm also
was evaluated in a conservative scenario that assumed no
interaction between chemotherapy beneﬁt and EPclin
score (ie, 0% interaction strength, constant HRtreatment). In
this scenario, the relative chemotherapy beneﬁt was equal
to the overall chemotherapy beneﬁt (β = 0; HRtreatment =
0.7; Fig 2).
After βmax was determined, risk of distant recurrence was
calculated for scenarios with a variety of interaction
strengths between EPclin and chemotherapy. Figure 3A
shows the relationship between EPclin score and predicted
risk of distant recurrence by 10 years for untreated and
treated patients under three scenarios of interaction
strength (0%, 50%, and 100%). In all cases, the risk of
TABLE 1. Absolute Chemotherapy Beneﬁt for Patients With Low and
High EPclin Scores Assuming Different Overall Relative Chemotherapy
Beneﬁt (20%, 30%, or 40%) for Different Relative Interaction
Strengths (0%, 50%, or 100%)
Absolute Chemotherapy
Beneﬁt (%)
20% Relative Chemotherapy Beneﬁt Low EPclin High EPclin
0% relative interaction (no interaction) 1.2 3.5
50% relative interaction 1.1 4.2
100% relative interaction (maximal) 1.0 4.9
30% Relative Chemotherapy Beneﬁt Low EPclin High EPclin
0% relative interaction (no interaction) 1.8 5.3
50% relative interaction 1.7 6.3
100% relative interaction (maximal) 1.5 7.3
40% Relative Chemotherapy Beneﬁt Low EPclin High EPclin
0% relative interaction (no interaction) 2.4 7.2
50% relative interaction 2.2 8.5
100% relative interaction (maximal) 2.0 9.6
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recurrence is low for low EPclin scores, which results in
small absolute chemotherapy beneﬁt. For example, the
expected absolute beneﬁt of chemotherapy treatment for
a patient with low EPclin scores ranged from0.3% (EPclin=1)
to 2.9% (EPclin = 3.3) for 0% interaction strength and
from 0% to 3.0% for 100% interaction strength. In com-
parison, there was much more separation between the
treated and untreated risk curves for patients with high
EPclin scores (Fig 3A). When there was no interaction, the
expected absolute beneﬁt of chemotherapy for high EPclin
scores ranged from 2.9% (EPclin = 3.3) to 12.8% (EPclin = 6).
This increased to a range of 3.0% to 28.5% for 100%
interaction strength. Similar results were obtained when
overall relative chemotherapy beneﬁt was modeled to be
lower (20%; Fig 3B) or higher (40%; Table 1; Fig 3C).
The various risk estimates across all scenarios of interaction
strength were applied to a clinical cohort of patients with
ER-positive, HER2-negative breast resections and repre-
sentative EPclin scores (n = 2,185). EPclin ranged from 1.3
to 6, with a mean EPclin score of 3.2 (standard deviation,
0.79). The full EPclin distribution is shown in Figure 4.
Overall, 1,275 samples (58%) were low risk, and 910
(42%) were high risk. The mean age at testing was 54.3
years, with the majority of patients having T1c or greater
tumors and node-negative disease (82.3% and 77.6%,
respectively; Table A1).
ln(HRtreatment) = ln(HRoverall) – (EPclin – EPclinavg)
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FIG 2. Patient beneﬁt from chemotherapy (HRtreatment) according to
EPclin score at no interaction (0%) and maximal interaction (100%).
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FIG 3. Risk of distant recurrence as a function of EPclin score for different interaction strengths under different
assumptions about overall relative chemotherapy beneﬁt: (A) 30%, (B) 20%, and (C) 40%. The threshold between
high (3.3 or greater) and low (less than 3.3) EPclin scores is shown by the dashed line.
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The absolute chemotherapy beneﬁt in low- and high-risk
patients was calculated as a function of interaction strength
(Fig 5). Absolute chemotherapy beneﬁt has an almost
linear dependence on interaction strength. The beneﬁt in
high-risk patients increases with an increase in the in-
teraction strength, whereas the beneﬁt in low-risk patients
decreases slightly. Of note, the effect of interaction strength
is moderate. Indeed, even with the strongest interaction,
the absolute chemotherapy beneﬁt for a 30% relative
beneﬁt in high-risk patients is 7.3%, which is not dra-
matically different from the 5.3% beneﬁt modeled in the
case of no interaction (Table 1). Similarly, in low-risk pa-
tients, the absolute beneﬁt is 1.5% when we assume the
strongest interaction, which is close to a 1.8% beneﬁt in the
case of no interaction.
DISCUSSION
Previous studies have demonstrated that EPclin accurately
identiﬁes patients at low risk for distant recurrence 10 years
after surgery, with improved prognostic performance
compared with clinical features alone or other molecular
tests.11,15-18 For these low-risk patients, it is clear that the
addition of adjuvant chemotherapy likely will not yield any
clinically meaningful risk reduction. However, the ability of
EPclin to predict chemotherapy beneﬁt has not been fully
explored. Here, we evaluated the capacity of EPclin to
identify patients with ER-positive, HER2-negative early-
stage breast cancer who may beneﬁt most from adding
adjuvant chemotherapy to ET. In addition, we examined
whether this chemopredictive capacity is driven by high
proﬁciency as a prognostic assay or as an interaction be-
tween EPclin score and chemotherapy. Thus, we evaluated
the impact by modeling across a range of potential che-
motherapy effects sizes and interaction strengths with
EPclin.
To minimize potential error associated with individual trial
values, the absolute beneﬁt of chemotherapy in women
with various EPclin scores was modeled using well-
established estimates of the average relative beneﬁt of
adjuvant chemotherapy. The risk of over- or under-
estimating risk can never be avoided entirely, despite best
efforts in trial design. This risk is particularly noteworthy in
studies of adjuvant interventions in early-stage breast
cancer because event rates may be low and distant re-
currence may manifest many years or even decades after
the initial diagnosis and treatment. In recognition of this,
investigators try to increase sample size, enrich for events,
and include the longest possible follow-up. Still, chemo-
therapy beneﬁt estimated from a single trial may be sig-
niﬁcantly inaccurate. To address potential single-study
error, we used the predicted chemotherapy beneﬁt de-
termined from a meta-analysis of data from 123 ran-
domized trials, which demonstrated that combination
chemotherapy reduced breast cancer distant recurrence
by approximately 30%.6 Using this information, as well as
estimates around this number (20% and 40%), we were
able to generate a reliable estimate of the beneﬁt of che-
motherapy in patients with breast cancer.
In all scenarios, there was little separation between the risk
curves for treated and untreated patients with low EPclin
scores (less than 3.3). As a result, the absolute predicted
chemotherapy beneﬁt in low-risk patients was small and
largely unaffected by average chemotherapy effect or in-
teraction strength, whereas the toxicity of therapy remains
the same. However, substantial separation existed between
the treated and untreated risk curves at all interaction
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strengths for high EPclin scores (3.3 or greater). This
separation increased at higher interaction strengths, and
the absolute beneﬁt in the high EPclin group ranged from
5.3% to 7.3% for a 30% average relative predicted che-
motherapy beneﬁt, which is substantially higher than dif-
ferences associated with different degrees of interaction.
Overall, these data demonstrate that high EPclin scores are
associated with maximal predicted chemotherapy beneﬁt,
and low EPclin scores are associated with no clinically
meaningful beneﬁt. This association is irrespective of in-
teraction strength between EPclin and predicted chemo-
therapy beneﬁt, and the impact of any interaction on
absolute beneﬁt is much smaller than the ability to accu-
rately estimate absolute risk.
As is typical of modeling studies, this study is not without
limitations. For example, this is not an analysis of samples
obtained from patients randomly assigned prospectively to
ET + C or ET alone. No such samples or data sets were
identiﬁed for retrospective analysis. Given current accepted
standards of care for patients with high-risk disease, future
studies that withhold chemotherapy for any of these pa-
tients are unlikely to occur. In addition, the overall predicted
chemotherapy beneﬁt used here was based on a meta-
analysis of 123 clinical studies, which included patients
treated with multiple different regimens. Inevitably, such
heterogeneity in chemotherapy regimens introduces vari-
ability in predicted chemotherapy beneﬁt. We sought to
offset such factors by modeling at a range of beneﬁt values
(20%, 30%, 40%). Of note, the approximately 30% re-
duction in distant recurrence was selected on the basis of
its association with chemotherapy regimens that are more
consistent with modern patterns of care in contrast to more
historic regimens.
Other aspects of the statistical model are also limitations of
the study. It is assumed that the relative beneﬁt of che-
motherapy linearly depends on EPclin score (Eq 2), which is
the simplest mathematical implementation of dependence.
Linear dependence also was used to demonstrate interaction
between chemotherapy and a prognostic score.8 In statistical
analysis, the most common implementation of interaction
between variables has the same functional form. In addition,
only positive interaction between chemotherapy beneﬁt and
EPclin score was included in this analysis because it is
expected that high expression of the proliferation-related
genes in EPclin is associated with higher rather than lower
relative chemotherapy beneﬁt. Conversely, high expres-
sion of the hormone receptor–related genes is expected to
be associated with smaller relative chemotherapy beneﬁt
because ER-negative tumors have a much stronger re-
sponse to chemotherapy than ER-positive tumors. This
again corresponds to a positive interaction because the
hormone receptor–related genes contribute negatively to
the EPclin score.
In summary, this modeling analysis demonstrates that
EPclin is able to predict which patients will gain maximum
absolute beneﬁt from chemotherapy. In addition, these
data indicate that the predicted absolute impact of che-
motherapy on distant recurrence depends much more on
the prognostic ability of the biomarker to predict an indi-
vidual woman’s risk of recurrence accurately. Therefore,
within a reasonable range, any interaction between EPclin
and relative predicted chemotherapy beneﬁt is a secondary
factor. EndoPredict has been shown in multiple studies to
predict risk of distant recurrence accurately in women with
ER-positive, HER2-negative early-stage breast cancer who
receive 5 years of ET, with an accuracy similar to the other
best breast prognostic tests and substantially better than
the 21-gene recurrence score (Oncotype DX; Genomic
Health, Redwood City, CA).18,24 This modeling indicates
that EndoPredict identiﬁed a substantial proportion of
women whose risk of breast cancer recurrence was so low
that the addition of adjuvant chemotherapy would not
produce a clinically meaningful beneﬁt on recurrence risk.
Conversely, patients with high EPclin scores were predicted
to experience the greatest beneﬁt from chemotherapy re-
gardless of the simulated interaction strength between
EPclin and predicted chemotherapy beneﬁt. Overall, this
demonstrates that EndoPredict provides guidance on the
expected absolute beneﬁt from adjuvant chemotherapy
in addition to prognostic information for patients with
ER-positive, HER2-negative early-stage breast cancer.
Therefore, EndoPredict can identify patients likely to beneﬁt
sufﬁciently from adjuvant chemotherapy to justify associ-
ated toxicities.
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APPENDIX
TABLE A1. Clinical Characteristics of the Tested Cohort
Cohort, No. (%)
Variable US Tested (n = 283) Munich Tested (n = 1,902) Full (N = 2,185)
Mean age, years (SD) 60.4 (10.6) 53.4 (10.1) 54.3 (10.4)
Missing 0 (0.0) 28 (1.5) 28 (1.3)
Tumor size
T1a 6 (2.1) 70 (3.7) 76 (3.5)
T1b 57 (20.1) 254 (13.4) 311 (14.2)
T1c 131 (46.3) 965 (50.7) 1,096 (50.2)
T2 88 (31.1) 587 (30.9) 675 (30.9)
T3 1 (0.4) 26 (1.4) 27 (1.2)
Nodal status
0 217 (76.7) 1,478 (77.7) 1,695 (77.6)
1-3 66 (23.3) 397 (20.9) 463 (21.2)
4-10 0 (0.0) 10 (0.5) 10 (0.5)
. 10 0 (0.0) 1 (0.1) 1 (0.0)
Missing 0 (0.0) 16 (0.8) 16 (0.7)
Abbreviation: SD, standard deviation.
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